Stay updated on Daratumumab Plus Ibrutinib in Waldenstrӧm's Clinical Trial
Sign up to get notified when there's something new on the Daratumumab Plus Ibrutinib in Waldenstrӧm's Clinical Trial page.

Latest updates to the Daratumumab Plus Ibrutinib in Waldenstrӧm's Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe page now displays the ClinicalTrials.gov record for a Phase 2 study of daratumumab plus ibrutinib for Waldenström macroglobulinemia, with study methods, eligibility, and outcome measures. It indicates the study was terminated for low accrual and is no longer seeking participants.SummaryDifference56%

- Check17 days agoChange DetectedThe footer revision label changed from `v3.7.2` to `v3.8.0`.SummaryDifference0.2%

- Check24 days agoChange DetectedA banner was added announcing changes to NIH terminology and linking to transition updates and FAQs.SummaryDifference1%

- Check31 days agoChange DetectedThe footer revision changed from v3.7.1 to v3.7.2, while the study record page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check38 days agoChange DetectedThe footer revision changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check58 days agoChange DetectedThe page now displays a 403 Forbidden error page, replacing the usual study content and navigation. This indicates restricted access to the study record and a disrupted user experience on this page.SummaryDifference20%

Stay in the know with updates to Daratumumab Plus Ibrutinib in Waldenstrӧm's Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab Plus Ibrutinib in Waldenstrӧm's Clinical Trial page.